Investing Center Preview – Manage your investments and watch your net worth grow.
ONC:NASDAQ – Large Cap Stock ()
BeOne Medicines AG – ONC Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
337.82 | 3.42 (+1.02%) | 170.99 - 351.27 | 112.4 thousand (Below Avg) |
Market data as of 4:00PM 09/22/25. Quotes are delayed by at least 15 min.
Overview - ONC
Open | 337.49 |
---|---|
Previous Close | 334.40 |
Day's Range | 334.40 - 339.67 |
Market Cap | 37.0B |
Avg Volume (10 Day) | 349.0K |
Price/Earnings (Trailing 12 Mo.) | -- |
Earnings Per Share (Trailing 12 Mo.) | -4.966 |
Dividend Yield | No Dividend |
One-Click Scorecard - ONC


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Neutral |
---|---|
Avoids excess debt? | Neutral |
Converting sales to profits? | Neutral |
Shareholder's money handled rationally? | Neutral |
Increased shareholder value? | Neutral |
Consistently increased owner earnings? | Neutral |
Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Neutral |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Neutral |
Stock is undervalued? | Neutral |
Have investors caught on? | Neutral |
Has support of institutional investors? | Neutral |
Has sufficient liquidity? | Neutral |
Latest Headlines - ONC
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Business Wire - Friday 08/29/2025 6:00 AM ET
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
Business Wire - Wednesday 08/27/2025 6:00 AM ET
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Business Wire - Tuesday 08/26/2025 6:01 AM ET
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
Business Wire - Monday 08/25/2025 6:00 AM ET
Industry Position - ONC
ONC | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 54.97% | |
Net Income Growth (1yr) | -- | |
Total Debt/Equity | 0.27 | |
LT Debt/Equity | 0.05 | |
Earnings Yield | -- | |
Price/Sales | 7.99 |
Competitors - ONC
Company | Last | Change |
---|
Data is delayed by at least 15 min.